Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Current Liabilities: 2015-2025

Historic Total Current Liabilities for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $93.7 million.

  • Intellia Therapeutics' Total Current Liabilities fell 11.31% to $93.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.7 million, marking a year-over-year decrease of 11.31%. This contributed to the annual value of $110.9 million for FY2024, which is 3.78% down from last year.
  • Per Intellia Therapeutics' latest filing, its Total Current Liabilities stood at $93.7 million for Q3 2025, which was down 1.86% from $95.5 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Total Current Liabilities registered a high of $131.1 million during Q3 2022, and its lowest value of $60.7 million during Q1 2021.
  • For the 3-year period, Intellia Therapeutics' Total Current Liabilities averaged around $102.9 million, with its median value being $103.4 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 107.75% in 2022, then declined by 29.88% in 2023.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Total Current Liabilities stood at $125.8 million in 2021, then grew by 0.57% to $126.6 million in 2022, then decreased by 8.97% to $115.2 million in 2023, then dropped by 3.78% to $110.9 million in 2024, then declined by 11.31% to $93.7 million in 2025.
  • Its last three reported values are $93.7 million in Q3 2025, $95.5 million for Q2 2025, and $112.6 million during Q1 2025.